DEFENCE THERAPEUTICS STRENGTHENS AND EXPANDS GLOBAL PATENT PROTECTION ON KEY
TECHNOLOGIES

EQS-News: Defence Therapeutics Inc. / Key word(s): Patent
DEFENCE THERAPEUTICS STRENGTHENS AND EXPANDS GLOBAL PATENT PROTECTION ON KEY
TECHNOLOGIES

14.05.2024 / 08:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE

DEFENCE THERAPEUTICS STRENGTHENS AND EXPANDS GLOBAL PATENT PROTECTION ON KEY
TECHNOLOGIES

Vancouver, BC, Canada, May 14, 2024 - Defence Therapeutics Inc. ("Defence"
or the "Company"), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian
biopharmaceutical company developing novel immune-oncology vaccines and drug
delivery technologies, is pleased to announce the issuance of several new
patents, as well as new allowances of patent applications belonging to
different Patent Families in Defence's vast and diverse portfolio.

Defence's vaccine enhancer platform technology based on simple admixture of
Accum® and variants thereof with specific antigens, is further expanded by
the recent allowance of Defence's US application no. 18/169,440 by the
USPTO. The newly allowed subject-matter, which includes valuable
composition-of-matter claims directed to Accum® or variants thereof as
standalone agents for enhancing antigen presentation, or in admixture with
of any vaccine antigen, elegantly compliments Defence's previously granted
US patent no. 11,612,651 covering methods of improving polypeptide antigen
immunogenicity. Importantly, this Patent Family is the first family broadly
covering Defence's anticancer ARM(TM) vaccine platform. Recent pre-clinical
studies using Defence's ARM-002(TM) vaccine suggest potent antitumor responses
in in vivo melanoma, lymphoma, and pancreatic cancer models when combined
with the anti-PD-1 immune-checkpoint inhibitor, paving the way for upcoming
Phase I clinical trials.

Defence is also pleased to announce the securing of a new patent in
Australia protecting its ADC platform technology based on the ability of the
original Accum® to form potent antibody-drug conjugates leading to targeted
cellular accumulation of a payload. Granted on February 1, 2024, Australian
patent no. 2017233725 broadly protects not only Defence's original Accum®
but also important variants thereof, which further strengthens the company's
patent protection in this valuable and growing therapeutic space. This
represents a significant milestone in the future development and
commercialization of novel ADCs for treating and detecting many cancers, and
adds to Defence's previous granted patents in the United States (US
11,352,437), Japan (JP 7,126,956), and Israel (IL 261765).

In addition, Defence's vaccine platform technology based on covalent
conjugation of Accum® and variants thereof to specific antigens, which
already included US patent no. 11,291,717, now includes Canadian patent no.
3,201,103 granted on December 12, 2023, as well as Australian patent no.
2021402007 granted on March 14, 2024. Furthermore, counterpart Japanese
application no. 2023-535891 was recently allowed by the Japanese Patent
Office and the Japanese patent is expected to be granted imminently. These
patents include claims broadly covering a method of improving polypeptide
antigen immunogenicity by covalently conjugating any antigen to Accum® or
any variant thereof, and also include independent composition-of-matter
claims covering potential vaccine compositions.

"We are thrilled to announce the issuance of these patents and allowances
with broad claims covering our ADC and vaccine platforms, which underscore
our relentless pursuit of innovation and our unwavering commitment to
improving human health" says Mr. Plouffe, CEO and president of Defence.

Acceleration of examination of the remaining applications in both of
Defence's vaccine platform Patent Families via the Patent Prosecution
Highway (PPH) program is currently being pursued based on these broad issued
and allowed claims. The issuance of new patents in these families is
therefore expected shortly.

About Defence:

Defence Therapeutics is a publicly-traded clinical-stage biotechnology
company working on engineering the next generation vaccines and ADC products
using its proprietary platform. The core of Defence Therapeutics platform is
the ACCUM® technology, which enables precision delivery of vaccine antigens
or ADCs in their intact form to target cells. As a result, increased
efficacy and potency can be reached against catastrophic illness such as
cancer and infectious diseases.

For further information:

Sebastien Plouffe, President, CEO and Director

P: (514) 947-2272

Splouffe@defencetherapeutics.com

www.defencetherapeutics.com

Cautionary Statement Regarding "Forward-Looking" Information

This release includes certain statements that may be deemed "forward-looking
statements". All statements in this release, other than statements of
historical facts, that address events or developments that the Company
expects to occur, are forward-looking statements. Forward-looking statements
are statements that are not historical facts and are generally, but not
always, identified by the words "expects", "plans", "anticipates",
"believes", "intends", "estimates", "projects", "potential" and similar
expressions, or that events or conditions "will", "would", "may", "could" or
"should" occur. Although the Company believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such
statements are not guarantees of future performance and actual results may
differ materially from those in the forward-looking statements. Factors that
could cause the actual results to differ materially from those in
forward-looking statements include regulatory actions, market prices, and
continued availability of capital and financing, and general economic,
market or business conditions. Investors are cautioned that any such
statements are not guarantees of future performance and actual results or
developments may differ materially from those projected in the
forward-looking statements. Forward-looking statements are based on the
beliefs, estimates and opinions of the Company's management on the date the
statements are made. Except as required by applicable securities laws, the
Company undertakes no obligation to update these forward-looking statements
in the event that management's beliefs, estimates or opinions, or other
factors, should change.

Neither the CSE nor its market regulator, as that term is defined in the
policies of the CSE, accepts responsibility for the adequacy or accuracy of
this release.


---------------------------------------------------------------------------

14.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Defence Therapeutics Inc.
                   1680 - 200 Burrard St
                   V6C3L6 Vancouver
                   Canada
   E-mail:         info@defencetherapeutics.com
   Internet:       https://defencetherapeutics.com
   ISIN:           CA24463V1013
   WKN:            A3CN14
   Listed:         Regulated Unofficial Market in Frankfurt, Stuttgart;
                   Toronto
   EQS News ID:    1901627

End of News EQS News Service
---------------------------------------------------------------------------

1901627 14.05.2024 CET/CEST